Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer By Ogkologos - April 7, 2026 176 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POLAR study Source RELATED ARTICLESMORE FROM AUTHOR How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... MOST POPULAR Flame of Hope Awards: Celebrating our volunteers April 3, 2023 FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... September 1, 2023 ESMO Congress 2022, 9-13 September August 22, 2022 FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and... September 25, 2025 Load more HOT NEWS ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... Gilteritinib Improves Survival in AML with FLT3 Mutations Cancer Research UK releases 2022 gender and ethnicity pay gap reports Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with...
